Literature DB >> 17716545

Serial procalcitonin responses in infection of children with secondary immunodeficiency.

M Hatzistilianou1, A Rekleity, F Athanassiadou, M A DeLutiis, P Conti, D Catriu.   

Abstract

PURPOSE: Procalcitonin has proven to be a sensitive inflammatory marker in non-neutropenic patients. The aim of this study was to determine and compare Procalcitonin with other inflammatory markers in the serum of immunosuppressed children with haematological malignancies; and to assess the predictive value of these mediators in distinguishing between bacterial and non-bacterial infection. METHODS &
RESULTS: The study included 37 children with acute lymphoblastic leukaemia undergoing intensive chemotherapy. They were divided into 3 groups, A, B and C. Group A consisted of 29 neutropenic children with 94 febrile episodes, group B of 20 neutropenic children with 56 afebrile episodes and group C of 13 non-neutropenic children with 58 afebrile episodes. Serial serum levels of PCT, C-Reactive Protein, Neopterin, Interleukin-6 and NO2/NO3 were all determined on a day-to-day basis for 7 consecutive days. In serum the concentrations of CRP was determined by nephelometry, of PCT by immunoluminescence and of Neopterin, IL-6 and NO2/NO3 by ELISA method.
CONCLUSIONS: According to our results the Procalcitonin concentration increased rapidly in patients with microbial infection; the response was detectable within 24 hs of the onset of fever due to microbial infections. Procalcitonin is a specific and sensitive marker of microbial infection in patients with neutropenic fever. The markers, C-Reactive Protein, Interleukin-6 and NO2/NO3 may not help to identify infections and distinguish the etiology of infection in neutropenic febrile children with acute lymphoblastic leukaemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17716545     DOI: 10.25011/cim.v30i2.983

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  7 in total

Review 1.  Immune regulation of procalcitonin: a biomarker and mediator of infection.

Authors:  G N Matwiyoff; J D Prahl; R J Miller; J J Carmichael; D E Amundson; G Seda; M Daheshia
Journal:  Inflamm Res       Date:  2012-02-22       Impact factor: 4.575

2.  Procalcitonin levels predict acute kidney injury and prognosis in acute pancreatitis: a prospective study.

Authors:  Hua-Lan Huang; Xin Nie; Bei Cai; Jiang-Tao Tang; Yong He; Qiang Miao; Hao-Lan Song; Tong-Xing Luo; Bao-Xiu Gao; Lan-Lan Wang; Gui-Xing Li
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

3.  Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia.

Authors:  Maria Hatzistilianou; Aleka Rekliti; Fanni Athanassiadou; Dorothea Catriu
Journal:  Inflamm Res       Date:  2009-10-06       Impact factor: 4.575

Review 4.  Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer.

Authors:  Robert S Phillips; Ros Wade; Thomas Lehrnbecher; Lesley A Stewart; Alex J Sutton
Journal:  BMC Med       Date:  2012-01-18       Impact factor: 8.775

5.  Prospective cohort study of procalcitonin levels in children with cancer presenting with febrile neutropenia.

Authors:  Victoria Hemming; Adam D Jakes; Geoff Shenton; Bob Phillips
Journal:  BMC Pediatr       Date:  2017-01-05       Impact factor: 2.125

6.  Diagnostic value of procalcitonin, C-reactive protein and lactate dehydrogenase in paediatric malignant solid tumour concurrent with infection and tumour progression.

Authors:  Fan Li; Weiling Zhang; Huimin Hu; Yi Zhang; Dongsheng Huang
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

7.  Biomarkers for Diagnosing Febrile Illness in Immunocompromised Children: A Systematic Review of the Literature.

Authors:  Fabian J S van der Velden; Andrew R Gennery; Marieke Emonts
Journal:  Front Pediatr       Date:  2022-03-10       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.